Abstract:Background and purpose: The production of metallo-ss-lactamases is a major mechanisms adopted by bacterial pathogens to resist carbapenems. Repurposing approved drugs to restore the efficacy of carbapenems represents an efficient and costeffective approach to fight infections caused by carbapenem resistant pathogens. Experimental approach: The nitrocefin hydrolysis assay was employed to screen potential New Delhi metallo-lactamase-1 (NDM-1) inhibitors from a commercially available U.S. Food and Drug Administration (FDA) approved drug library. The mechanism of inhibition was clarified by metal restoration, inductively coupled plasma mass spectrometry (ICP-MS) and molecular dynamics simulation. The in vitro synergistic antibacterial effect of the identified inhibitors with meropenem was determined by the checkerboard minimum inhibitory concentration (MIC) assay, time-dependent killing assay and combined disc test. Three mouse infection models were used to further evaluate the in vivo therapeutic efficacy of combined therapy. Key results: Twelve FDA-approved compounds were initially screened to inhibit the ability of NDM-1 to hydrolyse nitrocefin. Among these compounds, dexrazoxane, embelin, candesartan cilexetil and nordihydroguaiaretic acid were demonstrated to inhibit all tested metallo-ss-lactamases and showed an in vitro synergistic bactericidal effect with meropenem against metallo-ss-lactamases-producing bacteria. Dexrazoxane, embelin and candesartan cilexetil are metal ion chelating agents, while the inhibition of NDM-1 by nordihydroguaiaretic acid involves its direct binding to the active region of NDM-1. Furthermore, these four drugs dramatically rescued the treatment efficacy of meropenem in three infection models. Conclusions and implications: Our observations indicated that dexrazoxane, embelin, candesartan cilexetil and nordihydroguaiaretic acid are promising carbapenem adjuvants against metallo-ss-lactamases-positive carbapenem resistant bacterial pathogens.

1,2-Isoselenazol-3(2H)-one derivatives as NDM-1 inhibitors displaying synergistic antimicrobial effects with meropenem on NDM-1 producing clinical isolates

Discovery of Thiosemicarbazone Derivatives As Effective New Delhi Metallo-Β-lactamase-1 (NDM-1) Inhibitors Against NDM-1 Producing Clinical Isolates.

Quinolinyl sulfonamides and sulphonyl esters exhibit inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1)

Discovery of Isatin-Β-methyldithiocarbazate Derivatives As New Delhi Metallo- Β-Lactamase-1 (NDM-1) Inhibitors Against NDM-1 Producing Clinical Isolates

N-acylhydrazones confer inhibitory efficacy against New Delhi metallo-β-lactamase-1

Novel Mercapto Propionamide Derivatives with Potent New Delhi Metallo-β-Lactamase-1 Inhibitory Activity and Low Toxicity

Novel Metallo‐β‐lactamases Inhibitors Restore the Susceptibility of Carbapenems to New Delhi Metallo‐lactamase‐1 (ndm‐1)‐harbouring Bacteria

Diaryl-substituted thiosemicarbazone: A potent scaffold for the development of New Delhi metallo-β-lactamase-1 inhibitors

PHT427 as an effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor restored the susceptibility of meropenem against Enterobacteriaceae producing NDM-1

Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition

Systematic research of H2dedpa derivatives as potent inhibitors of New Delhi Metallo-β-lactamase-1

Design, synthesis and antibacterial activity evaluation of ebselen derivatives in NDM-1 producing bacteria

Pterostilbene Restores Carbapenem Susceptibility in New Delhi Metallo‐β‐lactamase‐producing Isolates by Inhibiting the Activity of New Delhi Metallo‐β‐lactamases

Dithiocarbamates combined with copper for revitalizing meropenem efficacy against NDM-1-producing Carbapenem-resistant Enterobacteriaceae

Stereochemically altered cephalosporins as potent inhibitors of New Delhi metallo-β-lactamases

Thiosemicarbazones exhibit inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1)

Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1).

Rational design of novel compounds to serve as potential NDM-1 inhibitors using molecular docking, molecular dynamics simulation, and physicochemical studies

Specific NDM-1 Inhibitor of Isoliquiritin Enhances the Activity of Meropenem Against NDM-1-positive Enterobacteriaceae in Vitro

A Novel Potent Metal-Binding NDM-1 Inhibitor Was Identified by Fragment Virtual, SPR and NMR Screening.

H2dpa Derivatives Containing Pentadentate Ligands: an Acyclic Adjuvant Potentiates Meropenem Activity in Vitro and in Vivo Against Metallo-Β-lactamase-producing Enterobacterales.